

Polatuzumab vedotin-piiq (ADC)

Summary

Catalog No.	DHE26399
Alternative Names	Polivy
Clone ID	Polatuzumab vedotin-piiq
Species reactivity	Human
Form	Liquid
Concentration	1 mg/ml
Purity	>90% as determined by SEC.
Clonality	Monoclonal
Applications	Research Grade Biosimilar
Target	CD79b
Purification	Purified by Ion Exchange Chromatography.
Endotoxin level	Please contact with the lab for this information.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Note	For research use only. Not suitable for clinical or therapeutic use.

Description

Polatuzumab vedotin (Polivy) is an ADC consisting of a CD79b-directed antibody and Monomethyl auristatin E (MMAE) that can be used in combination with bendamustine and rituximab for the treatment

Recombinant Proteins & Antibodies

of adult patients with at least two relapses or refractory diffuse large B-cell lymphoma. Polatuzumab vedotin binds to CD79b and is internalized by tumor cells. MMAE is cleaved from cells by lysosomal protease and promotes tumor cell apoptosis by inhibiting microtubule formation.

Data Image
